Genmab downgraded after HuMax-CD20 success brings "unneccesary" R&D cost rise

 
• By Simon Varcoe
  
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category